Carl Byrnes
Stock Analyst at Northland Capital Markets
(1.38)
# 3,140
Out of 4,810 analysts
23
Total ratings
37.5%
Success rate
-0.02%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $22.08 | +40.40% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $5.55 | +125.23% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $8.32 | +50.24% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $1.25 | +380.00% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.36 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $2 → $1.25 | $9.47 | -86.80% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $8 | $0.39 | +1,959.20% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $19.36 | +313.22% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $6.77 | +239.73% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.00 | +2,302.16% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $1.00 | +199,900.00% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.93 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $22.08
Upside: +40.40%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $5.55
Upside: +125.23%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $8.32
Upside: +50.24%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $1.25
Upside: +380.00%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.36
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $2 → $1.25
Current: $9.47
Upside: -86.80%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $8
Current: $0.39
Upside: +1,959.20%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $19.36
Upside: +313.22%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $6.77
Upside: +239.73%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.00
Upside: +2,302.16%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $1.00
Upside: +199,900.00%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.93
Upside: -